Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
May 25, 2017 NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for th...
May 19, 2017 NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has received a 2017 Industry Innovation Award from the ...
May 17, 2017 NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:...
May 4, 2017 Worldwide net Ocaliva® (obeticholic acid or OCA) 1Q 2017 sales of $20.6 millionCompleted enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019 Conference call scheduled for 8:30 a....
Apr 27, 2017 NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017 financial results prior to the NASDAQ market open o...
Apr 19, 2017 NEW YORK, April 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid, INT-767 and preclinical research...
Mar 30, 2017 NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference: ...
Mar 16, 2017 NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:...
Mar 2, 2017 First new medication for primary biliary cholangitis in nearly 20 years Rapid NICE approval only two months after marketing authorization in the EU; one of the fastest approvals to date for an orphan medicine NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Intercep...
Feb 23, 2017 Net Ocaliva® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 net sales of $18.2 million...
Page:
1
... NextLast
= add release to Briefcase